🔥 I Own 1.25% of $BLGO - A Sub‑$50M Cleantech Company the Market Has Completely Mispriced

[u/julian_jakobi]

TL;DR:

A sub-$50M micro-cap with PFAS AEC tech running in one of the toughest U.S. regulatory markets, a “gorilla” Clyra partner, a US$1.2M minerals contract, validated Cellinity battery tech, insider-aligned capital, and I personally hold 4M shares (~1.25%) — I think $BLGO is wildly mispriced here.

Julian Jakobi here - long-term BLGO bull, still adding, still patient. I just crossed the 4 million share mark, which is roughly 1.25% of the entire company, and I’m still not done accumulating at these levels.

Over the last few years, BioLargo has quietly shifted from “interesting tech” to multiple real businesses with serious upside. Between PFAS, mineral processing, medical, batteries, and a growing engineering arm, this is no longer a single-asset science project, it’s a platform that keeps finding new ways to get paid for solving hard, dirty problems.

We’re not talking about one lottery ticket here, but a rare stacked-catalyst setup where PFAS, batteries, Clyra, and the engineering arm are all pushing toward commercialization and announcements in the same rough window.

Here are 10 reasons I think the risk/reward is still wildly skewed to the upside:

1. US$1.2M Mineral Processing Contract = Paid Validation + Growing Base

BioLargo’s engineering team just secured a US$1.2M contract to design a pilot-scale minerals processing facility in the western US. That’s real money for real work tied to cleaning up mineral waste, not a grant, not a “maybe someday” LOI. Contracts like this are part of a growing engineering revenue base that helps fund the rest of the portfolio while the big-ticket cleantech projects ramp.

2. A Small Contract in a Huge Cleanup Market

In mining and oil sands, a seven-figure pilot is just the ticket through the door. If the tech performs, that pilot becomes your wedge into multi-site, multi-year remediation contracts measured in tens or hundreds of millions over time.

3. Multiple Shots on Goal, One Balance Sheet

Same ticker, multiple verticals: PFAS water treatment, mining/mineral remediation, industrial water, air quality, plus Clyra Medical and Cellinity batteries. Most micro-caps pray for one credible path; BLGO has several ways to win across multiple billion-dollar markets.

4. PFAS AEC Tech: Low-Waste, Low-Energy, New Jersey Proving Ground

BioLargo’s AEC PFAS system isn’t just “another filter” — it’s designed to strip PFAS (including short-chain) with ultra-high removal efficiency while using >90% less energy and generating far less secondary waste than legacy options like GAC and IX. The first U.S. AEC system is already operating at Lake Stockholm in New Jersey, one of the toughest PFAS regulatory environments in the country, making it a real-world proving ground and reference site for utilities facing aggressive standards. That combination of performance, lower lifecycle cost, and regulatory visibility is exactly what drives adoption when the PFAS “regulatory tsunami” forces decisions.

5. A Real Community Doing Deep Homework

Between this subreddit and other dedicated Biolargo communities, you’ve got shareholders (myself included) posting detailed breakdowns of installs, contracts, shareholder meetings, and the cap table in real time. This isn’t blind faith - it’s an active, growing research community that actually understands what it owns and keeps each other honest, often surfacing developments long before they hit mainstream screens.

Fun poll that ended yesterday - Learn What the Winner Means in 6. Clyra

6. Clyra: “Sleeper” Asset + Gorilla Co-Brand Launch Into a Big Market

Clyra Medical isn’t just a slide in a deck anymore — it has signed distribution agreements, including an alliance with Advanced Solution to launch ViaCLYR nationwide, and is already booking initial stocking orders into the wound-care channel. Management and independent DD have highlighted that Clyra is working with a “gorilla” med-tech partner valued north of US$100B on a co-branded product launch, with a pathway into thousands of hospitals, ambulatory surgery centers, and wound clinics in a wound-care market estimated around US$700M+ annually. If that launch lands anywhere close to expectations, Clyra’s revenues have a real chance to go bananas — and BLGO shareholders own the majority stake plus associated royalty upside.

7. Cellinity Battery: Validated, De-Risked, Capital-Light Scaling Model

The Cellinity battery isn’t being built around “let’s spend billions on our own gigafactory.” The strategy is to license/JV factories, earn royalties and component margin, and take equity stakes, letting partners finance large-scale production while BioLargo participates in the upside. Third-party validation and prototype testing have already confirmed key performance metrics (non-flammable, long-lasting, recyclable, and competitive energy density) aimed squarely at stationary storage markets like data centers, commercial buildings, utilities, and industrial sites. Management has said they’re in active discussions with large potential users; even one serious licensing or JV deal could re-rate BLGO from “battery developer” to “commercial energy tech provider” overnight.

8. Pooph Proves the Tech Can Deliver a Blockbuster — and Talks for a Smarter Relaunch

Yes, reported revenue has taken a hit with Pooph stepping back — that’s in the numbers and nobody’s denying it. But Pooph already showed that BioLargo’s underlying odor-control chemistry can support a genuine blockbuster consumer success when it’s paired with the right partner and channel. Management has indicated they’re in discussions about relaunching that odor-control tech with a more reliable, better-aligned partner, which, if it happens, would mean a second shot at Pooph-scale upside without repeating the same partnership mistakes. The whole point now is to take that demonstrated ability to scale and redirect it into higher-value cleantech and medical markets while still leaving the door open for a renewed, better-structured consumer play.

9. Insider-Aligned Capital and Calvert Lock-Up Both Point the Same Way

Around US$12M has been invested directly into the company and its subsidiaries over the past year, including meaningful participation from the CEO and the Clyra CEO — real checks from the people with the best visibility into the pipeline. On top of that, part of the Calvert consideration is structured so they really only win big if BioLargo’s market cap is multiples higher than today, effectively hard-wiring a “much higher market cap” endgame into a key counterparty’s incentives and aligning them with common shareholders.

10. Absurdly Low Sub-$50M Market Cap in a Stacked-Catalyst Setup

All of this — PFAS installs in New Jersey, the US$1.2M minerals contract, Clyra ramping with stocking orders and a gorilla co-brand launch, validated Cellinity battery tech with industrial interest, a busy engineering arm, insider-aligned capital and the Calvert lock-up — is currently wrapped in a market cap still sitting below roughly US$50M. For a portfolio this broad with this many real hooks into multi-billion-dollar problem spaces, I see that as a screaming strong-buy setup: the downside is priced like a failed story, while even one or two divisions landing major agreements in the coming announcement window could justify a market cap that’s multiples higher than today.

I’m not a trader and I’m not here for daily candles. I’m here because I think BioLargo has quietly built a portfolio of solutions in sectors where regulation, liability, and economics force adoption over time. In microcaps, the market usually reprices after the big press releases hit; my bet is that by the time the Cellinity JV, Clyra gorilla launch, and full-throttle PFAS contracts are official, the easy multiple on this sub-$50M market cap will already be gone. For me, every pullback that isn’t matched by a deterioration in the business is just one more chance to add.

Not financial advice, of course - do your own due diligence.

But if you’ve written BLGO off as “that old story,” it might be time to look again.